Jiangsu Hengrui Pharmaceuticals (1276) Announces New Board Election and Director Changes

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (1276) disclosed proposals for the tenth session of its Board, including re-elections, an independent non-executive director’s retirement, and a new appointment.

The new Board is planned to comprise eleven directors, including six executive directors, one non-executive director, and four independent non-executive directors. Subject to approval at the 2025 annual general meeting (AGM), proposed re-elections include five executive directors and three independent non-executive directors, as well as the continuation of one non-executive director. If approved, terms for these directors will span three years from the date of the AGM.

An independent non-executive director, Mr. Dong Jiahong, will retire at the conclusion of the AGM. His positions as an independent non-executive director and chairperson or member of various Board committees will cease accordingly. The announcement confirms that there are no outstanding disagreements or matters requiring attention regarding his retirement.

In addition, the Board proposes appointing Mr. Lou Liguang as an independent non-executive director. Pending AGM approval, his term will align with the tenth session of the Board. Concurrently, an internal employee representative meeting re-elected Mr. Sun Jieping as employee representative director.

The Company indicates that remuneration for these proposed directors will be decided by the Board after approval at the AGM, taking into account their responsibilities, the Company’s remuneration policy, and market conditions. Official details of all proposed directors and other relevant information will be available in the AGM circular to be distributed on the websites of the Hong Kong Stock Exchange and the Company.

According to the announcement, certain directors are currently interested in the Company’s shares either directly or through shareholding structures. Notably, one director is deemed interested in 1.54 billion A shares. Each independent non-executive director candidate has confirmed adherence to the independence criteria under applicable listing rules.